These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24568463)

  • 1. Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
    Prajoko YW; Aryandono T
    Asian Pac J Cancer Prev; 2014; 15(2):595-8. PubMed ID: 24568463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
    Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
    Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
    Khokher S; Qureshi MU; Mahmood S; Nagi AH
    Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
    Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
    Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of nuclear factor-κB in female breast cancer: a study in Indian patients.
    Jana D; Das S; Sarkar DK; Mandal S; Maji A; Mukhopadhyay M
    Asian Pac J Cancer Prev; 2012; 13(11):5511-5. PubMed ID: 23317209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-κb), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients.
    Prajoko YW; Aryandono T
    Asian Pac J Cancer Prev; 2019 May; 20(5):1511-1518. PubMed ID: 31128056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression].
    Liu C; Zhou S; Ke CS; Li NP; Wu RL
    Ai Zheng; 2007 Sep; 26(9):929-36. PubMed ID: 17927847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.
    Aleskandarany MA; Green AR; Rakha EA; Mohammed RA; Elsheikh SE; Powe DG; Paish EC; Macmillan RD; Chan S; Ahmed SI; Ellis IO
    Int J Cancer; 2010 Apr; 126(7):1761-9. PubMed ID: 19711345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
    Yuan SF; Zhu LJ; Zheng WE; Chen H; Wu LL; Zhang W; Sun HY; Chen WJ
    Asian Pac J Cancer Prev; 2012; 13(1):361-5. PubMed ID: 22502701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.
    Jones LW; Fels DR; West M; Allen JD; Broadwater G; Barry WT; Wilke LG; Masko E; Douglas PS; Dash RC; Povsic TJ; Peppercorn J; Marcom PK; Blackwell KL; Kimmick G; Turkington TG; Dewhirst MW
    Cancer Prev Res (Phila); 2013 Sep; 6(9):925-37. PubMed ID: 23842792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
    Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
    Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer.
    Chung HC; Rha SY; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Lee KB
    Breast Cancer Res Treat; 1997 Jan; 42(1):65-72. PubMed ID: 9116319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.